安胃疡胶囊辅助治疗消化性溃疡的实践与评估

李丽丽

【摘要】 目的：探討安胃疡胶囊辅助治疗消化性溃疡的实践与评估。方法：选取2017年10月-2018年10月于本院就诊的消化性溃疡患者84例，按照随机数字表法将患者分为试验组（n=42）和对照组（n=42）。所有患者均进行四联疗法，试验组患者在此基础上服用安胃疡胶囊辅助治疗，两组均连续治疗4周。治疗结束后，观察比较两组患者的临床疗效、幽门螺杆菌（Hp）清除率、血清学指标及不良反应发生率。结果：试验组的总有效率为95.24%，高于对照组的76.19%，差异有统计学意义（P<0.05）。试验组Hp清除率为92.86%，高于对照组的71.43%，差异有统计学意义（P<0.05）。与治疗前比较，两组患者治疗后血清ET、IL-6、TNF-α水平均降低，血清NO、VEGF水平均升高，差异均有统计学意义（P<0.05）;且试验组这些观察指标的改善程度均优于对照组（P<0.05）。治疗后，试验组患者的CD4+ T、CD4+ T/CD8+ T均显著高于对照组（P<0.05），CD8+ T显著低于对照组（P<0.05）。两组患者的不良反应发生率比较，差异无统计学意义（P>0.05）。结论：安胃疡胶囊辅助治疗消化性溃疡可有效增强临床效果，提高Hp清除率，改善血清细胞因子水平，提高患者免疫力且不良反应轻微，具有较好的临床推广应用价值。

【关键词】 安胃疡胶囊; 消化性溃疡; 幽门螺杆菌; 血清学指标

【Abstract】 Objective：To explore the practice and evaluation of Anweiyang Capsule in the treatment of peptic ulcer.Method：84 patients with peptic ulcer who were treated in our hospital from October 2017 to October 2018 were selected，they were divided into experimental group（n=42）and control group（n=42）according to random number table method.All patients were given quadruple therapy，the experimental group was given Anweiyang Capsule as adjuvant therapy on this basis，and the two groups were treated continuously for 4 weeks.After treatment，the clinical efficacy，clearance rate of Helicobacter pylori（Hp），serological indicators and incidence of adverse reactions were observed and compared between the two groups.Result：The total effective rate of the experimental group was 95.24%，higher than 76.19% of the control group，the difference was statistically significant（P<0.05）.The Hp clearance rate in the experimental group was 92.86%，higher than 71.43% in the control group，the difference was statistically significant（P<0.05）.Compared with before treatment，serum ET，IL-6，TNF-α levels were all decreased and serum NO and VEGF levels were all increased in the two groups after treatment，with statistically significant differences（P<0.05）;and the improvement degree of these observation indicators in the experimental group were better than those in the control group（P<0.05）.After treatment，CD4+ T，CD4+ T/CD8+ T in the experimental group were significantly higher than those in the control group（P<0.05），and CD8+ T was significantly lower than that in the control group（P<0.05）.There was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）.Conclusion：Anweiyang Capsule as an adjuvant treatment for peptic ulcer can effectively enhance the clinical effect，improve the clearance rate of Hp，improve the level of serum cytokines，improve the immunity of patients and the adverse reactions is mild，and has good clinical application value.

【Key words】 Anweiyang Capsule; Peptic ulcer; Helicobacter pylori; Serological indicators

First-authors address：Dongguan Peoples Hospital，Dongguan 523059，China

doi：10.3969/j.issn.1674-4985.2019.08.020

消化性潰疡是消化系统的常见病，在我国的发病率高达15%～30%，具有病程长、易复发等特点，极易并发穿孔、出血、梗阻，甚至癌变，严重影响患者生活质量[1]。临床上，常规治疗方法为抗Hp四联疗法，但是由于现代人对于抗生素的滥用以及长期使用抗生素疗法引起的Hp耐药，使得该疗法的疗效下降[2]。目前，中药在调节机体免疫、气血亏虚及脾胃不和等症状上具有独到的优势，特别在抗Hp等方面逐渐表现出明显优势。文献[3]研究显示，安胃疡胶囊在治疗消化性溃疡并减少复发中有一定效果。因此，本文主要研究安胃疡胶囊辅助治疗消化性溃疡的临床效果和可行性，旨在指导临床用药治疗，现将研究结果报道如下。……